Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence

Kevin J. Harrington, Christophe Le Tourneau, Denis Soulières et al.|Oral Oncology|2023

Cited by 17